Table 1.
Patients' characteristics.
# | Sex | Age (yrs) | EGFR type | Tissues and genetic testing | |||
---|---|---|---|---|---|---|---|
Before osimertinib | After osimertinib | ||||||
1 | F | 62 | L858R | Lung | NGS | Pleura | NGS |
2 | M | 85 | 19 del | SL | ARMs-PCR | Lung | NGS |
3 | M | 66 | 19 del | Bone | ARMs-PCR | Lung | NGS |
4 | F | 79 | L858R | Lung | ARMs-PCR | Lung | NGS |
5 | F | 89 | 19 del | Lung | NGS | Lung | NGS |
6 | F | 66 | 19 del | Serum | ARMs-PCR | Bone | NGS |
7 | M | 56 | 19 del | Lung | ARMs-PCR | Lung | NGS |
8 | F | 75 | 19 del | Pleura | ARMs-PCR | Pleura | NGS |
9 | M | 51 | 19 del | Lung | ARMs-PCR | Lung | NGS |
Median | 66 |
SL denotes supraclavicular lymph node.